switching from compounded semaglutide to wegovy Diabetes advocacy group discourages use of GLP-1 drugs FDA ends semaglutide shortage, closing

Type 2 diabetes affects over 500 million people worldwide, and obesity affects more than 890 million

That approach is changing rapidly

Improving on Current-Generation GLP-1s Looking Forward With the treatment landscape in such upheaval, experts are hesitant to predict what the future of obesity and diabetes treatment will look like

However, dropout rates exceed 40% by month three, and weight regain is common after program discontinuation, suggesting behavioral tools alone may not address underlying metabolic drivers

It represents the date through which the manufacturer guarantees the product will maintain its labeled potency and safety when stored according to the label instructions